A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020
NCT ID: NCT01744808
Last Updated: 2014-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
54 participants
INTERVENTIONAL
2013-02-28
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Food on Evacetrapib (LY2484595) in Healthy Participants
NCT01810432
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
NCT02044406
A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
NCT05797701
To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).
NCT01145014
A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants
NCT06670950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To investigate the safety and tolerance of a single oral dose of a SR formulation of EB-1020 in the fed and fasted state.
* To investigate the safety, tolerance, and cognitive effects of multiple oral rising doses of a SR formulation of EB-1020.
Secondary Objectives
* To characterize the single dose and steady state pharmacokinetic profiles of EB-1020 SR formulations.
* To investigate the effect of food on the pharmacokinetic profile of EB-1020 SR following single oral doses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EB-1020 SR1
Sustained release formulation
EB-1020 SR1
sustained release
EB-1020 SR2
Sustained Release Formulation
EB-1020 SR2
Sustained release
EB-1020 SR3
Sustained Release Formulation
EB-1020 SR3
Sustained release
EB-1020 IR
Immediate Release Formulation
EB-1020 IR
Immediate release
Placebo
Placebo Formulation
Placebo
Placebo formulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EB-1020 IR
Immediate release
EB-1020 SR1
sustained release
EB-1020 SR2
Sustained release
EB-1020 SR3
Sustained release
Placebo
Placebo formulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight with the normal range for height (body mass index \[BMI\] between 19-30 kg/m2 inclusive)
3. If female, be of non-child bearing potential (surgically sterile, post-menopausal for 12 months or receiving a stable dose of implanted or injectable contraceptive for at least 3 months with last dose of injectable contraceptive within 2 months). Non-surgical menopause history must be confirmed by follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels as defined by established lab ranges.
4. Be in general good health without clinically significant medical history
5. Have clinical laboratory test results that are within the laboratory reference range; or if out of range are not clinically relevant and are acceptable to the Investigator and Sponsor medical representative
6. Negative Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis Screening test
7. Able and willing to give written informed consent
Exclusion Criteria
2. Use of prescription drugs within 4 weeks prior to first dosing. Subjects who have used over the counter medication excluding paracetamol, topical over the counter medications and routine vitamins but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as non-clinically relevant by the Principal Investigator and Sponsor
3. A history of, or current evidence for, suicidal ideation, based upon clinical interview and a psychiatric questionnaire
4. A history of known or suspected seizures, spasms, infantile spasms, febrile convulsions, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits)
5. A history of sleep problems in the last 3 months
6. A history of relevant atopy or drug hypersensitivity
7. A history (within the last 5 years) or evidence of alcohol or drug abuse. Subject who consume more than 14 units (female) or 21 (male) units of alcohol a week (unit = 1 glass (125 mL) of wine = 1 measure of spirits = ½ pint of beer) will also be ineligible
8. A positive urine test for drugs of abuse or alcohol at Screening or on the day of admittance to the Study Unit
9. A history of smoking in the last 3 months
10. Have a significant infection (such as influenza) or known inflammatory process on screening or admission
11. Have acute gastrointestinal symptoms at the time of screening or admission (e.g. nausea, vomiting, diarrhea, heartburn )
12. Have previously received EB-1020
13. Be vegetarians, vegans or have medical dietary restrictions
14. Any major surgical procedure within one month of entry into the study
15. Have difficulties communicating reliably with the Investigator or appear unlikely to co-operate with the requirements of the study in the investigator's judgment.
16. Any other condition which in the view of the Investigator is likely to interfere with study or put the subject at risk.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neurovance, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network Ltd.
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EB-1020-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.